Share on StockTwits

Merck & Co (NYSE:MRK) announced a quarterly dividend on Tuesday, February 25th, StockRatingsNetwork reports. Stockholders of record on Monday, March 17th will be paid a dividend of 0.44 per share on Monday, April 7th. This represents a $1.76 annualized dividend and a dividend yield of 3.13%.

MRK has been the subject of a number of recent research reports. Analysts at TheStreet reiterated a “buy” rating on shares of Merck & Co in a research note on Wednesday, February 19th. On the ratings front, analysts at Zacks reiterated a “neutral” rating on shares of Merck & Co in a research note on Thursday, February 6th. They now have a $56.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. raised their price target on shares of Merck & Co from $55.00 to $60.00 in a research note on Thursday, February 6th. One analyst has rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $55.56.

Merck & Co (NYSE:MRK) traded up 0.07% during mid-day trading on Tuesday, hitting $56.22. 4,033,525 shares of the company’s stock traded hands. Merck & Co has a one year low of $42.10 and a one year high of $56.92. The stock’s 50-day moving average is $53.10 and its 200-day moving average is $49.19. The company has a market cap of $164.3 billion and a price-to-earnings ratio of 38.22.

Merck & Co (NYSE:MRK) last released its earnings data on Wednesday, February 5th. The company reported $0.88 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.88. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $11.39 billion. During the same quarter last year, the company posted $0.83 earnings per share. Merck & Co’s revenue was down 3.6% compared to the same quarter last year. Analysts expect that Merck & Co will post $3.45 EPS for the current fiscal year.

In other Merck & Co news, EVP Clark Golestani sold 5,990 shares of the stock on the open market in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $55.47, for a total value of $332,265.30. Following the transaction, the executive vice president now directly owns 6,046 shares in the company, valued at approximately $335,372. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.